An international research team has discovered two previously unknown viruses in short-finned pilot whales and orcas from the Caribbean region of the North Atlantic Ocean. The group includes students and senior scientists from Arizona State…
Author: admin
-
Venezuelans are reacting to Maduro’s capture with anger, fear, hope and joy
When the news broke of Nicolás Maduro’s arrest following a US attack on Venezuela on January 3, que locura (“what madness”) was the line that seemed to capture the moment. As Venezuelans around the world reached for their phones and…
Continue Reading
-
Integrated multispectral remote sensing and field investigations for delineating ophiolitic complexes of Wadi Ghadir southeastern desert Egypt
EL, S., EL Bayoumi, R. M. & Egypt. The ophiolited of wadi Ghadir area (Eastern Desert, 1979).
Hassan, M. A. & Hashad, A. H. & EL-MEZAIN, A. A proposed mode of emplacement of El-Fawakhir ophiolites. (1983).
Ela, A. E., Farahat, E. S. & F. F. &…
Continue Reading
-
From London to Broadway: Discover the new shows hopping the pond this spring
This London bridge isn’t falling down anytime soon. Every NYC theatre season brings an array of imports from England, adding a dash of West End magic to the Broadway and Off-Broadway theatrical mix.
The pipeline between the West End and Broadway…
Continue Reading
-
Apollo to Announce Fourth Quarter and Full Year 2025 Financial Results on February 9, 2026Apollo Global Management
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) plans to release financial results for the fourth quarter and full year 2025 on Monday, February 9, 2026, before the opening of trading on the New York Stock Exchange. Management will review Apollo’s financial results at 8:30 am ET via public webcast available on Apollo’s Investor Relations website at ir.apollo.com. A replay will be available one hour after the event.
Apollo distributes its earnings releases via its website and email lists. Those interested in receiving firm updates by email can sign up for them here.
About Apollo
Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Our patient, creative, and knowledgeable approach to investing aligns our clients, businesses we invest in, our employees, and the communities we impact, to expand opportunity and achieve positive outcomes. As of September 30, 2025, Apollo had approximately $908 billion of assets under management. To learn more, please visit www.apollo.com.
Contacts
Noah Gunn
Global Head of Investor Relations
Apollo Global Management, Inc.
(212) 822-0540
IR@apollo.comJoanna Rose
Global Head of Corporate Communications
Apollo Global Management, Inc.
(212) 822-0491
Communications@apollo.comContinue Reading
-
Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study
SPRING HOUSE, Pa., (January 6, 2026) – Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a Phase 3 program. The JASMINE study met the primary endpoint (percentage of patients achieving Systemic Lupus Erythematosus Responder Index [SRI-4]a composite response at Week 24 with statistical significance compared with placebo), and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparing. Nipocalimab had a safety and tolerability profile consistent with previous Phase 2 studies, with no new safety signals identified.
These data represent the first positive results of an investigational FcRn blocker treatment in this chronic, debilitating autoantibody-driven disease that impacts an estimated 3 to 5 million people worldwide, and 450,000 in the U.S.1,2 , Chronic symptoms of SLE include severe fatigue, joint pain and swelling, and rashes, including a hallmark butterfly-shaped facial rash.3
JASMINE is a 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of nipocalimab in 228 adult participants with active SLE and the first positive study of an FcRn blocker for the treatment of active SLE.4
“Systemic lupus erythematosus or SLE is a serious autoantibody-driven disease that can impact multiple organ systems, significantly reducing health-related quality of life for millions of people,” said Leonard L. Dragone, M.D., Ph.D., Disease Area Leader, Autoantibody and Rheumatology, Johnson & Johnson Innovative Medicine. “Many people living with SLE also face complications associated with long-term steroid use, underscoring the limitations of current treatment approaches and the critical need for immunoselective therapies that are safe, tolerable, and capable of reducing disease activity, while preserving immune function.”
Full results from the JASMINE study will be presented at a future medical congress.
Editor’s note:
a. The SLE Responder Index 4 (SRI-4) is a composite measure used to assess treatment response in patients with SLE during clinical studies. It comprises criteria from three different internationally validated indices, SELENA-SLE Disease Activity Index (SELENA-SLEDAI), Physician Global Assessment (PGA) and the British Isles Lupus Assessment Group (BILAG) 2004.ABOUT JASMINE
JASMINE (NCT04882878) is a 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of nipocalimab in 228 adult participants with active SLE and the first positive study of an FcRn blocker for the treatment of active SLE.4ABOUT SYSTEMIC LUPUS ERYTHEMATOSUS
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that occurs when the body’s immune system mistakenly attacks its own healthy tissues. This can lead to inflammation and damage in many parts of the body, including the skin, joints, heart, lungs, kidneys, and brain. SLE affects nine times more women than men, often striking initially between the ages of 15-44.7 In addition to systemic organ damage, other complications of SLE can include end-stage renal failure, scarring cutaneous lesions, neurological damage, and various forms of cardiovascular disease.5 People living with SLE often face reduced health-related quality of life, due to severe fatigue, mood disturbances, joint pain and swelling, and rashes, including the hallmark butterfly-shaped facial rash, as well as complications of long-term glucocorticoid use.3 Severe fatigue is the most widely reported and debilitating symptom of SLE, affecting up to 80% of people with SLE. SLE is the most common form of lupus, affecting 3 to 5 million people worldwide, approximately 70% of lupus cases.1,7 It is estimated that 450,000 people in the United States are affected by SLE.2ABOUT NIPOCALIMAB
Nipocalimab is an investigational monoclonal antibody, designed to bind with high affinity to block FcRn and reduce levels of circulating immunoglobulin G (IgG) antibodies potentially without additional detectable effects on other adaptive and innate immune functions. This includes autoantibodies and alloantibodies that underlie multiple conditions across three key segments in the autoantibody space including Rare Autoantibody diseases, Maternal Fetal diseases mediated by maternal alloantibodies and autoantibody-driven Rheumatic diseases.8,9,10,11,12,13,14,15,16 Blockade of IgG binding to FcRn in the placenta is also believed to limit transplacental transfer of maternal alloantibodies to the fetus.17,18The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted several key designations to nipocalimab including:
• EU EMA Orphan medicinal product designation for hemolytic disease of the fetus and newborn (HDFN) in October 2019 and fetal and neonatal alloimmune thrombocytopenia (FNAIT) in April 2025
• U.S. FDA Fast Track designation in HDFN and warm autoimmune hemolytic anemia (wAIHA) in July 2019, gMG in December 2021, FNAIT in March 2024 and Sjögren’s disease (SjD) in March 2025
• U.S. FDA Orphan drug status for wAIHA in December 2019, HDFN in June 2020, gMG in February 2021, chronic inflammatory demyelinating polyneuropathy (CIDP) in October 2021 and FNAIT in December 2023
• U.S. FDA Breakthrough Therapy designation for HDFN in February 2024 and for Sjögren’s disease in November 2024
• U.S. FDA granted Priority Review in generalized myasthenia gravis in Q4 2024ABOUT JOHNSON & JOHNSON
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com.
Follow us at @JNJInnovMed.
Janssen Research & Development, LLC, Janssen Biotech, Inc. and Janssen Global Services, LLC are Johnson & Johnson companies.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of nipocalimab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.Footnotes
1 Tian, J., Zhang, D., Yao, X., Huang, Y., & Lu, Q. (2023). Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study. Annals of the Rheumatic Diseases, 82(3), 351–356. https://doi.org/10.1136/ard-2022-223035
2 Wang, Y., Hester, L. L., Lofland, J., Rose, S., Karyekar, C.S., Kern, D.M., Blacketer, M., Davis, K., & Sheilds-Tuttle, K. (2022). Update on the prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016. BMC Research Notes, 15, 5. https://doi.org/10.1186/s13104-021-05877-1
3 Centers for Disease Control and Prevention. (2024). Symptoms of lupus. https://www.cdc.gov/lupus/signs-symptoms/. Last accessed: January 2026.
4 ClinicalTrials.gov Identifier: NCT04882878. Available at: https://clinicaltrials.gov/study/NCT04882878. Last accessed: January 2026.
5 National Institute of Arthritis and Musculoskeletal and Skin Disease. (2022) Systemic Lupus Erythematosus (Lupus). https://www.niams.nih.gov/health-topics/lupus. Last accessed: January 2026.
6 Ahn, G.E., & Ramsey-Goldman, R. (2012). Fatigue systemic lupus erythematosus. International Journal of Clinical Rheumatology, 7(2), 217–227. https://doi.org/10.2217/IJR.12.4
7 Lupus Foundation of America. Lupus facts and statistics. https://www.lupus.org/resources/lupus-facts-and-statistics. Last accessed: January 2026.
8 ClinicalTrials.gov. NCT03842189. Available at: https://clinicaltrials.gov/ct2/show/NCT03842189. Last accessed: January 2026.
9 ClinicalTrials.gov Identifier: NCT05327114. Available at: https://www.clinicaltrials.gov/study/NCT05327114. Last accessed: January 2026.
10 ClinicalTrials.gov Identifier: NCT04119050. Available at: https://clinicaltrials.gov/study/NCT04119050. Last accessed: January 2026.
11 ClinicalTrials.gov Identifier: NCT05379634. Available at: https://clinicaltrials.gov/study/NCT05379634. Last accessed: January 2026.
12 ClinicalTrials.gov Identifier: NCT05912517. Available at: https://www.clinicaltrials.gov/study/NCT05912517. Last accessed: January 2026.
13 ClinicalTrials.gov Identifier: NCT04968912. Available at: https://www.clinicaltrials.gov/study/ NCT04968912. Last accessed: January 2026.
14 ClinicalTrials.gov Identifier: NCT04882878. Available at: https://clinicaltrials.gov/study/NCT04882878. Last accessed: January 2026.
15 ClinicalTrials.gov Identifier: NCT06449651. Available at: https://clinicaltrials.gov/study/ NCT06449651. Last accessed: January 2026.
16 ClinicalTrials.gov Identifier: NCT06533098. Available at: https://clinicaltrials.gov/ct2/show/NCT06533098. Last accessed: January 2026.
17 Lobato G, Soncini CS. Relationship between obstetric history and Rh(D) alloimmunization severity. Arch Gynecol Obstet. 2008 Mar;277(3):245-8. DOI: 10.1007/s00404-007-0446-x. Last accessed: January 2026.
18 Roy S, Nanovskaya T, Patrikeeva S, et al. M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model. Am J Obstet Gynecol. 2019;220(5):498 e491-498 e499.
Continue Reading
-
Blackstone Energy Transition Partners Announces Acquisition of Alliance Technical Group
New York, NY – January 6, 2026 – Blackstone (NYSE: BX) announced today that funds affiliated with Blackstone Energy Transition Partners and other Blackstone funds (“Blackstone”) have acquired Alliance Technical Group (“ATG”), a leading provider of environmental testing, monitoring, and compliance services.
Founded in 2000 and headquartered in Alabama, ATG has grown into one of the largest full-service environmental compliance providers in North America, with more than 2,200 employees located in 60-plus offices and labs across the U.S. and Canada. ATG delivers a comprehensive suite of solutions – including source and lab testing, continuous emission monitoring systems (CEMS), and leak detection and repair, among others – to help businesses maintain regulatory compliance and safety, while driving efficiency through ATG’s data-driven insights.
Chris LeMay, Chief Executive Officer at Alliance Technical Group, said: “Blackstone’s investment is a testament to our strong organic and strategic growth as a trusted market leader in the testing, inspection and compliance sector. With our partners at Blackstone, we look forward to continuing to scale and support our customers in navigating a complex, evolving regulatory landscape.”
Darius Sepassi, Senior Managing Director, and Mark Henle, Managing Director, at Blackstone, said: “Alliance is a clear market leader in emissions testing and monitoring, providing mission-critical services that directly support customers’ compliance and operational performance. Chris and the ATG management team have built a diversified platform with a strong reputation for technical quality and reliability. Together, we are excited to leverage Blackstone’s scale and resources to help support ATG’s continued growth, serving its existing and new customers across the power, energy and industrial sectors.”
David Foley, Global Head of Blackstone Energy Transition Partners, added: “Our investment strategy focuses on identifying leading businesses that we believe are positioned to disproportionately benefit from the growing demand for electricity and the broader energy transition. We are excited to back Alliance, which plays a critical role in helping energy and industrial facilities operate safely, efficiently, and in compliance with environmental regulations.”
Alliance Technical Group represents the latest in a number of recent transactions Blackstone Energy Transition Partners has announced behind its high-conviction investment themes in electricity demand growth and the ongoing energy transition, including Maclean Power Systems, Wolf Summit Energy, Hill Top Energy Center, Shermco, Enverus, Lancium, Westwood, and others.
Terms of the transaction were not disclosed. Harris Williams and RBC acted as financial advisor and Kirkland & Ellis acted as a legal advisor to Blackstone. Piper Sandler served as financial advisor and Jones Day served as a legal advisor to Alliance.
About Blackstone Energy Transition Partners
Blackstone Energy Transition Partners is Blackstone’s strategy for control-oriented equity investments in energy-related businesses, a leading energy investor with a successful long-term record, having committed over $27 billion of equity globally across a broad range of sectors within the energy industry. Our investment philosophy is based on backing exceptional management teams with flexible capital to provide solutions that help energy companies grow and improve performance, thereby delivering more reliable, affordable and cleaner energy to meet the growing needs of the global community. In the process, we build stronger, larger scale enterprises, create jobs and generate lasting value for our investors, employees and all stakeholders. Further information is available at https://www.blackstone.com/our-businesses/blackstone-energy-transition-partners/.
About Blackstone
Blackstone is the world’s largest alternative asset manager. Blackstone seeks to deliver compelling returns for institutional and individual investors by strengthening the companies in which the firm invests. Blackstone’s over $1.2 trillion in assets under management include global investment strategies focused on real estate, private equity, credit, infrastructure, life sciences, growth equity, secondaries and hedge funds. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, X (Twitter), and Instagram.
About Alliance Technical Group
Alliance Technical Group, LLC (Alliance), headquartered in Decatur, AL, is the premier environmental services and solutions company dedicated to helping facilities achieve their environmental goals and navigate regulatory changes through the company’s On-site Testing and Monitoring, Environmental Compliance, and Laboratory Testing and Analysis offerings. Driven by innovation, committed to service, and focused on client success, Alliance delivers on the promise of responsiveness, reliability, and results. Learn more about how Alliance helps clients maximize their environmental opportunities: www.alliancetg.com
Media Contacts
Blackstone
Jennifer Heath
[email protected]
Alliance Technical Group
Jarred Smith
[email protected]
Continue Reading
-
Convocatoria del Real Madrid para la Supercopa de España
Esta es la convocatoria del Real Madrid para disputar en Yeda la Supercopa de España. Los de Xabi Alonso se enfrentarán en las semifinales al Atlético en el estadio Rey Abdullah (jueves, 20:00 hora española, 22:00 hora local; Orange TV y…
Continue Reading
-
Actress and singer says she quit her ‘toxic mom group’
Singer and actress Ashley Tisdale has spoken out about being “brought to tears” by being a member of a “toxic mom group”, which she ultimately decided to leave.
The US actress rose to fame as a child star on the Disney Channel and later appeared…
Continue Reading
-
Honor Power 2 Keeps Up a Nuclear Reactor Sized Battery in a Slim Profile
Until recently, smartphones with batteries larger than 5,000mAh were usually bulky and rugged devices. Advances in silicon-carbon (Si/C) anode battery technology have changed that. Higher energy density cells now allow manufacturers to…
Continue Reading